FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1907083095> ?p ?o ?g. }

• W1907083095 endingPage "182" @default.
• W1907083095 startingPage "172" @default.
• W1907083095 abstract "Julie S. Barber-Rotenberg 1 , Saravana P. Selvanathan 1 , Yali Kong 1 , Hayriye V. Erkizan 1 , Tara M. Snyder 2 , S. Peter Hong 3 , Christina L. Kobs 3 , Natalie L. South 3 , Steven Summer 3 , Philip J. Monroe 3 , Maksymilian Chruszcz 4 , Veselin Dobrev 5 , Perrer N. Tosso 1 , Lauren J. Scher 1 , Wladek Minor 4 , Milton L. Brown 1 , Steven J. Metallo 5 , Aykut Üren 1 , and Jeffrey A. Toretsky 1 1 Department of Oncology, Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC USA 2 AMRI, Pharmaceutical and Quality Services, Albany, NY USA 3 Battelle Memorial Institute, Health and Life Sciences, Columbus, OH USA 4 Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA USA 5 Department of Chemistry, Georgetown University, Washington, DC USA Received: February 17, 2012; Accepted: February 26, 2012; Published: February 29, 2012; Keywords: PRL-3 monoclonal antibody, PRL-3 mouse/human chimeric antibody, antibody therapy, intracellular oncoprotein Correspondence: Jeffrey A. Toretsky, // // Abstract Oncogenic fusion proteins, such as EWS-FLI1, are excellent therapeutic targets as they are only located within the tumor. However, there are currently no agents targeted toward transcription factors, which are often considered to be ‘undruggable.’  A considerable body of evidence is accruing that refutes this claim based upon the intrinsic disorder of transcription factors.  Our previous studies show that RNA Helicase A (RHA) enhances the oncogenesis of EWS-FLI1, a putative intrinsically disordered protein.  Interruption of this protein-protein complex by small molecule inhibitors validates this interaction as a unique therapeutic target.  Single enantiomer activity from a chiral compound has been recognized as strong evidence for specificity in a small molecule-protein interaction.  Our compound, YK-4-279, has a chiral center and can be separated into two enantiomers by chiral HPLC.  We show that there is a significant difference in activity between the two enantiomers.  (S)-YK-4-279 is able to disrupt binding between EWS-FLI1 and RHA in an immunoprecipitation assay and blocks the transcriptional activity of EWS-FLI1, while (R)-YK-4-279 cannot.  Enantiospecific effects are also established in cytotoxicity assays and caspase assays, where up to a log-fold difference is seen between (S)-YK-4-279 and the racemic YK-4-279.  Our findings indicate that only one enantiomer of our small molecule is able to specifically target a protein-protein interaction. This work is significant for its identification of a single enantiomer effect upon a protein interaction suggesting that small molecule targeting of intrinsically disordered proteins can be specific. Furthermore, proving YK-4-279 has only one functional enantiomer will be helpful in moving this compound towards clinical trials. &nbsp" @default.
• W1907083095 created "2016-06-24" @default.
• W1907083095 creator A5001084611 @default.
• W1907083095 creator A5006256074 @default.
• W1907083095 creator A5006511805 @default.
• W1907083095 creator A5008552666 @default.
• W1907083095 creator A5019326307 @default.
• W1907083095 creator A5030736508 @default.
• W1907083095 creator A5037125511 @default.
• W1907083095 creator A5039319953 @default.
• W1907083095 creator A5045963629 @default.
• W1907083095 creator A5047748993 @default.
• W1907083095 creator A5053517863 @default.
• W1907083095 creator A5060409332 @default.
• W1907083095 creator A5060470978 @default.
• W1907083095 creator A5066652067 @default.
• W1907083095 creator A5074137694 @default.
• W1907083095 creator A5081082781 @default.
• W1907083095 creator A5083229382 @default.
• W1907083095 creator A5083341315 @default.
• W1907083095 creator A5086720797 @default.
• W1907083095 date "2012-02-29" @default.
• W1907083095 modified "2023-10-15" @default.
• W1907083095 title "Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1" @default.
• W1907083095 cites W1480948328 @default.
• W1907083095 cites W1539796472 @default.
• W1907083095 cites W1598164462 @default.
• W1907083095 cites W1967700202 @default.
• W1907083095 cites W1970352766 @default.
• W1907083095 cites W1973206059 @default.
• W1907083095 cites W1980480652 @default.
• W1907083095 cites W1990200822 @default.
• W1907083095 cites W2006585685 @default.
• W1907083095 cites W2007438323 @default.
• W1907083095 cites W2013083986 @default.
• W1907083095 cites W2016170088 @default.
• W1907083095 cites W2025527937 @default.
• W1907083095 cites W2041002214 @default.
• W1907083095 cites W2042244296 @default.
• W1907083095 cites W2042380110 @default.
• W1907083095 cites W2061891797 @default.
• W1907083095 cites W2066280610 @default.
• W1907083095 cites W2069351898 @default.
• W1907083095 cites W2073745520 @default.
• W1907083095 cites W2075479290 @default.
• W1907083095 cites W2081578121 @default.
• W1907083095 cites W2093544430 @default.
• W1907083095 cites W2102443458 @default.
• W1907083095 cites W2121158863 @default.
• W1907083095 cites W2122260140 @default.
• W1907083095 cites W2127221680 @default.
• W1907083095 cites W2131350133 @default.
• W1907083095 cites W2150318080 @default.
• W1907083095 cites W2151444534 @default.
• W1907083095 cites W2159650080 @default.
• W1907083095 cites W2170213020 @default.
• W1907083095 cites W2272982156 @default.
• W1907083095 cites W2317783677 @default.
• W1907083095 cites W4210968583 @default.
• W1907083095 doi "https://doi.org/10.18632/oncotarget.454" @default.
• W1907083095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3326647" @default.
• W1907083095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22383402" @default.
• W1907083095 hasPublicationYear "2012" @default.
• W1907083095 type Work @default.
• W1907083095 sameAs 1907083095 @default.
• W1907083095 citedByCount "79" @default.
• W1907083095 countsByYear W19070830952012 @default.
• W1907083095 countsByYear W19070830952013 @default.
• W1907083095 countsByYear W19070830952014 @default.
• W1907083095 countsByYear W19070830952015 @default.
• W1907083095 countsByYear W19070830952016 @default.
• W1907083095 countsByYear W19070830952017 @default.
• W1907083095 countsByYear W19070830952018 @default.
• W1907083095 countsByYear W19070830952019 @default.
• W1907083095 countsByYear W19070830952020 @default.
• W1907083095 countsByYear W19070830952021 @default.
• W1907083095 countsByYear W19070830952022 @default.
• W1907083095 countsByYear W19070830952023 @default.
• W1907083095 crossrefType "journal-article" @default.
• W1907083095 hasAuthorship W1907083095A5001084611 @default.
• W1907083095 hasAuthorship W1907083095A5006256074 @default.
• W1907083095 hasAuthorship W1907083095A5006511805 @default.
• W1907083095 hasAuthorship W1907083095A5008552666 @default.
• W1907083095 hasAuthorship W1907083095A5019326307 @default.
• W1907083095 hasAuthorship W1907083095A5030736508 @default.
• W1907083095 hasAuthorship W1907083095A5037125511 @default.
• W1907083095 hasAuthorship W1907083095A5039319953 @default.
• W1907083095 hasAuthorship W1907083095A5045963629 @default.
• W1907083095 hasAuthorship W1907083095A5047748993 @default.
• W1907083095 hasAuthorship W1907083095A5053517863 @default.
• W1907083095 hasAuthorship W1907083095A5060409332 @default.
• W1907083095 hasAuthorship W1907083095A5060470978 @default.
• W1907083095 hasAuthorship W1907083095A5066652067 @default.
• W1907083095 hasAuthorship W1907083095A5074137694 @default.
• W1907083095 hasAuthorship W1907083095A5081082781 @default.
• W1907083095 hasAuthorship W1907083095A5083229382 @default.
• W1907083095 hasAuthorship W1907083095A5083341315 @default.
• W1907083095 hasAuthorship W1907083095A5086720797 @default.

• next